A Phase II, Open Label, Multicenter Study to Evaluate the Efficacy and Safety of TT-00420 (Tinengotinib) Tablet in Adult Patients With Advanced Cholangiocarcinoma
Latest Information Update: 08 Jul 2024
At a glance
- Drugs Tinengotinib (Primary)
- Indications Cholangiocarcinoma
- Focus Therapeutic Use
- Sponsors TransThera Biosciences
Most Recent Events
- 08 Jul 2024 Last checked against Clinicaltrials.gov record.
- 24 Apr 2024 Status changed from active, no longer recruiting to completed.
- 20 Jan 2024 Results (As of 7Aug2023, n=48 )presented at the 2024 Gastrointestinal Cancers Symposium